Form 8-K AbbVie Inc. For: Oct 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
AbbVie reports $2.7 billion IPR&D expense to impact Q3 earnings
October 3, 2025 4:10 PM EDTAbbVie Inc. (NYSE: ABBV) announced that its third quarter 2025 earnings will include $2.7 billion in acquired intellectual property research and development and milestones expense on a pre-tax basis. The pharmaceutical company said this expense will reduce both GAAP diluted earnings per share and adjusted... More
